Gilead Sciences (NASDAQ:GILD) Given Buy Rating at Piper Sandler

Piper Sandler restated their buy rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Thursday morning, TipRanks reports. Piper Sandler currently has a $90.00 price objective on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other reports. Bank of America raised their price objective on Gilead Sciences from $70.00 to $72.00 and gave the stock a neutral rating in a research report on Wednesday, February 5th. Needham & Company LLC reissued a hold rating on shares of Gilead Sciences in a research report on Sunday, April 19th. Raymond James downgraded Gilead Sciences from an outperform rating to a market perform rating in a research report on Friday, May 1st. Mizuho restated a buy rating and set a $81.00 target price on shares of Gilead Sciences in a report on Wednesday, May 13th. Finally, SunTrust Banks cut Gilead Sciences from a hold rating to a sell rating and set a $70.00 target price for the company. in a report on Friday, May 1st. Seven research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have assigned a buy rating to the company. Gilead Sciences has an average rating of Hold and an average price target of $78.15.

Shares of GILD traded down $0.16 during midday trading on Thursday, reaching $73.34. The company had a trading volume of 6,235,402 shares, compared to its average volume of 20,370,521. The firm has a 50 day simple moving average of $77.81 and a 200-day simple moving average of $70.11. The company has a quick ratio of 2.92, a current ratio of 3.04 and a debt-to-equity ratio of 1.00. The stock has a market cap of $91.85 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 3.16 and a beta of 0.72. Gilead Sciences has a 1-year low of $60.89 and a 1-year high of $85.97.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.11. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company earned $1.67 EPS. As a group, sell-side analysts anticipate that Gilead Sciences will post 6.34 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Friday, June 12th will be paid a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.71%. The ex-dividend date is Thursday, June 11th. Gilead Sciences’s payout ratio is 44.30%.

In related news, CAO Diane E. Wilfong sold 12,264 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $80.09, for a total transaction of $982,223.76. Following the completion of the sale, the chief accounting officer now owns 23,685 shares in the company, valued at $1,896,931.65. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Brett A. Pletcher sold 13,210 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $79.23, for a total value of $1,046,628.30. Following the transaction, the executive vice president now directly owns 27,204 shares in the company, valued at approximately $2,155,372.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,585 shares of company stock valued at $4,671,283. 0.13% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GILD. Capital International Investors increased its position in Gilead Sciences by 336.8% during the first quarter. Capital International Investors now owns 56,369,657 shares of the biopharmaceutical company’s stock worth $4,214,200,000 after buying an additional 43,464,551 shares during the period. Capital World Investors increased its position in Gilead Sciences by 123.0% during the first quarter. Capital World Investors now owns 46,331,318 shares of the biopharmaceutical company’s stock worth $3,463,732,000 after buying an additional 25,555,467 shares during the period. Norges Bank acquired a new position in Gilead Sciences during the fourth quarter worth approximately $859,602,000. Capital Research Global Investors increased its position in Gilead Sciences by 12.7% during the first quarter. Capital Research Global Investors now owns 95,982,319 shares of the biopharmaceutical company’s stock worth $7,175,643,000 after buying an additional 10,849,434 shares during the period. Finally, Valueworks LLC increased its position in Gilead Sciences by 7,777.5% during the fourth quarter. Valueworks LLC now owns 4,919,000 shares of the biopharmaceutical company’s stock worth $6,146,000 after buying an additional 4,856,556 shares during the period. 77.34% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: Preferred Stock

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.